^
    Back
    Association details:
    Biomarker:CCNE1 overexpression
    Cancer:Ovarian Cancer
    Drug:adavosertib (AZD1775) (WEE1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Targeting Cyclin E1 altered high grade serous ovarian cancer (HGSC)

    Excerpt:
    ...Patient’s tumour has a confirmed Cyclin E over-expression defined by IHC...
    Trial ID:
    ACTRN12619001185156
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

    Published date:
    04/16/2021
    Excerpt:
    Six patients (14%) had confirmed partial responses (PR): 4 ovarian, 2 endometrial….We determined the once-daily adavosertib RPh2D and observed activity in patients with ovarian or endometrial carcinoma, including 2 with baseline CCNE1 mRNA overexpression.
    DOI:
    10.1158/1078-0432.CCR-21-0329